Loading...
•
Dec 31, 2023
GoodRx Q4 2023 Earnings Report
Reported fourth quarter and full year 2023 results, showing revenue and adjusted revenue increased by 7% to $196.6 million, driven by prescription transactions.
Key Takeaways
GoodRx's Q4 2023 results showed a 7% increase in revenue and adjusted revenue to $196.6 million. The company reported a net loss of $25.9 million, while adjusted EBITDA reached $57.3 million. The company exited the quarter with over 7 million consumers of prescription-related offerings.
Revenue and Adjusted Revenue increased 7% to $196.6 million.
Net loss was $25.9 million, with a net loss margin of 13.2%.
Adjusted EBITDA was $57.3 million, resulting in an Adjusted EBITDA Margin of 29.1%.
The company repurchased $77.8 million in shares of Class A common stock.
Revenue by Segment
Forward Guidance
For Q1 2024, GoodRx anticipates revenue and Adjusted Revenue between $195 million and $198 million, with an Adjusted EBITDA Margin in the high twenty-percent range, potentially up to 30%. For the full year 2024, the company expects revenue and Adjusted Revenue to be approximately $800 million and Adjusted EBITDA of approximately $250 million.
Positive Outlook
- First quarter revenue and Adjusted Revenue are expected to grow by 6% to 8% year-over-year.
- Adjusted EBITDA Margin is expected to be in the high twenty-percent range, potentially up to 30% for the first quarter.
- Full year revenue and Adjusted Revenue are projected to be around $800 million.
- Adjusted EBITDA for the full year is expected to be approximately $250 million.
- Balance sheet and liquidity position remained strong.
Challenges Ahead
- Full year growth rates are tempered by the approximately $25 million topline impact associated with pharma manufacturer solutions restructuring.
- Consumer incentives are expected to reduce revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...